# Clopidogrel

Drug · id `cardio:clopidogrel` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Plavix

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke  

## In plain language

Clopidogrel, sold as Plavix, is an antiplatelet medicine of the P2Y12 inhibitor class. The US label read lists it to lower the rate of heart attack and stroke for people with acute coronary syndrome (unstable angina or non-ST-elevation heart attack, and ST-elevation heart attack managed medically), and for people with an established peripheral arterial disease, a recent heart attack or a recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.

## Technical summary

RxNorm ingredient 32968. UNII 08I79HTP27 is the UNII of clopidogrel bisulfate, the salt the label names, and is a broad match. The label read is the Sanofi-Aventis U.S. LLC label for Plavix, application NDA020839, effective 2025-05-30 in openFDA. Other clopidogrel labels in openFDA, including generic products and repackagers, were not read. This page records label indications, the title of the boxed warning and the class only: no trial result and no dose is given.

## Claims, with the population each applies to

## Context: People for whom the US label of clopidogrel (Plavix) lists an indication: acute coronary syndrome, acute ST-elevation myocardial infarction managed medically, recent myocardial infarction, recent stroke, established peripheral arterial disease

Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)

### The US label of Plavix (clopidogrel), in the Sanofi-Aventis U.S. LLC version dated 2025-05-30 in openFDA, lists the medicine to reduce the rate of myocardial infarction and stroke in patients with acute coronary syndrome without ST-segment elevation (unstable angina or non-ST-elevation myocardial infarction), in patients with acute ST-elevation myocardial infarction who are to be managed medically, and in patients with established peripheral arterial disease or a history of recent myocardial infarction or recent stroke. The label carries a boxed warning titled diminished antiplatelet effect in patients with two loss-of-function alleles of the CYP2C19 gene.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Patients described in the indications section of the label. The label passages read do not state an age range.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications, the title of the boxed warning and the mechanism sentence were read; contraindications, doses, interactions and other warnings were not recorded. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-11-09
- Sources:
  1. Supports: openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective\_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22de8b0b67-eb25-4684-83b5-7ad785314227%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1 INDICATIONS AND USAGE. Retrieved 2026-11-09T13:16:08Z. Source state: Current. Version fingerprint: 5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c.
     How it applies: Label passage quoted in the research quote table (LB-04).
  2. Supports: openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective\_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22de8b0b67-eb25-4684-83b5-7ad785314227%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Acute Coronary Syndrome (ACS). Retrieved 2026-11-09T13:16:08Z. Source state: Current. Version fingerprint: 5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c.
     How it applies: Label passage quoted in the research quote table (LB-05).
  3. Supports: openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective\_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22de8b0b67-eb25-4684-83b5-7ad785314227%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1 Acute Coronary Syndrome (ACS), STEMI sentence. Retrieved 2026-11-09T13:16:08Z. Source state: Current. Version fingerprint: 5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c.
     How it applies: Label passage quoted in the research quote table (LB-06).
  4. Supports: openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective\_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22de8b0b67-eb25-4684-83b5-7ad785314227%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease. Retrieved 2026-11-09T13:16:08Z. Source state: Current. Version fingerprint: 5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c.
     How it applies: Label passage quoted in the research quote table (LB-07).
  5. Supports: openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective\_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22de8b0b67-eb25-4684-83b5-7ad785314227%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], title. Retrieved 2026-11-09T13:16:08Z. Source state: Current. Version fingerprint: 5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c.
     How it applies: Label passage quoted in the research quote table (LB-08).
  6. Background: openFDA drug label record for PLAVIX (clopidogrel tablets), Sanofi-Aventis U.S. LLC label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id de8b0b67-eb25-4684-83b5-7ad785314227 (manufacturer Sanofi-Aventis U.S. LLC, application NDA020839), returned on 2026-11-09. The label text is dated 2025-05-30 (effective\_time). Other openFDA records of clopidogrel labels, including generic products and repackagers, exist and were not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22de8b0b67-eb25-4684-83b5-7ad785314227%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-11-09T13:16:08Z. Source state: Current. Version fingerprint: 5953f77cb9817a2f028855472c54858e95f0a79e190c3f802587c0fd8207371c.
     How it applies: Effective date of the label text read, 20250530.

## Connected pages

- Clopidogrel is a P2Y12 platelet inhibitor (FDA established pharmacologic class in RxClass): P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- FDA label lists non-ST-segment elevation acute coronary syndrome as an indication: Acute coronary syndrome (`cardio:acute-coronary-syndrome`) [a claim, not a settled fact; see claim `cardio:claim-fda-clopidogrel-label-indications` and its context]
- FDA label lists acute ST-elevation myocardial infarction managed medically as an indication: ST-elevation heart attack (STEMI) (`cardio:stemi`) [a claim, not a settled fact; see claim `cardio:claim-fda-clopidogrel-label-indications` and its context]
- FDA label lists a history of recent myocardial infarction as an indication: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`) [a claim, not a settled fact; see claim `cardio:claim-fda-clopidogrel-label-indications` and its context]
- FDA label lists recent stroke as an indication: Stroke (`core:stroke`) [a claim, not a settled fact; see claim `cardio:claim-fda-clopidogrel-label-indications` and its context]
- FDA label lists established peripheral arterial disease as an indication: Peripheral artery disease (`cardio:peripheral-artery-disease`) [a claim, not a settled fact; see claim `cardio:claim-fda-clopidogrel-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry product
- 109 registry trials

## Provenance

Content hash: 8e607e6e86e22dce3dbc717d293d344c57781197029baf8482e1a487e5fd776d
Last substantive edit: 2026-11-09
Evidence last checked: 2026-11-09
